Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmPR Newswire·Jul 21 at 06:29 PMRGNX-5.07%
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Whybenzinga_article·Jul 21 at 02:52 PMRGNX-5.07%ADCT-5.74%
U.S. stock market midday update: Regenxbio up 8.90%, long-term effectiveness of gene therapy drives positive sentimentPrice Alert·Jul 20 at 02:12 PMRGNX-5.07%
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatmentsbenzinga_article·Jul 20 at 09:45 AMRGNX-5.07%
REGENXB priced $9.00 IPO of 10.0M shares plus 1.11M pre-funded warrants, raising ~$107.8M netTradingView·Jul 20 at 06:43 AMRGNX-5.07%
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingUnusual Whales·Jul 18 at 02:38 PMRGNX-5.07%
Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meetingPUBT·Jul 18 at 01:55 PMRGNX-5.07%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Jul 17 at 07:05 AMLIMN-6.57%RGNX-5.07%
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·Jul 17 at 07:02 AMRGNX-5.07%STAA-3.35%
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants | RGNX Stock NewsStockTitan·Jul 16 at 10:00 PMRGNX-5.07%
